StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$6.51−0.94 (-12.62%)

Close on Nov 12, 2026Market cap $12.67MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$12.67M
P/E ratio
–
Price to sales
–
Price to book
0.72
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$29.40M
EPS, diluted
$0.00
Book value per share
$0.00
Diluted shares
265.89B

Trading

Previous close
$7.45
Open
$7.49
Day's range
$6.51 – $7.69
Volume
14,523
Average volume (20 days)
42,356
Beta (5 years)
1.12
52-week range
$3.02 – $29.32
RSI (14 days)
39.8
Volatility (1 year)
294.8%
Relative volume
0.26×
WACC
10.6%

Market cap history

Month-end market cap since 2014, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

PeriodAKTXS&P 500DifferenceAKTX per yearS&P 500 per year
1 month-23.8%-2.7%−21.1 pts
3 months-9.3%-1.7%−7.6 pts
Year to date-43.7%+11.9%−55.6 pts
1 year-70.0%+12.0%−82.0 pts
3 years-95.2%+78.2%−173.4 pts-63.6%+21.2%
5 years-99.5%+73.2%−172.7 pts-65.5%+11.6%
10 years-99.9%+309.6%−409.6 pts-50.1%+15.1%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Operating income

-$28.27M

Net income

-$29.40M

EPS, diluted

$0.00

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Akari Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated
    Results
  2. Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration
    Results
  3. Therapeutics Announces ADS Ratio Change
    Update
  4. Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
    Update
  5. 8-K exhibit EX-99.1
    Update
  6. 8-K exhibit EX-99.1
    Update
All press releases and earnings

About Akari Therapeutics

Pharmaceutical Preparations

The provided text does not contain factual descriptions or narrative details concerning what the company does, its specific products, operational segments, or customer base. The text consists entirely of XBRL metadata tags, SEC filing identifier codes, dates, and accounting taxonomy members relating to shares, notes, and warrants.

Company profile, executives and history

Akari Therapeutics stock: common questions

What is Akari Therapeutics's stock price?

AKTX closed at $6.51 on Nov 12, 2026, down 12.62% on the day. Over the past 52 weeks it traded between $3.02 and $29.32.

What is Akari Therapeutics's market cap?

Akari Therapeutics was worth $12.67M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.

What is AKTX's P/E ratio?

Akari Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.

Does Akari Therapeutics pay a dividend?

No. Akari Therapeutics has not paid a cash dividend over the last twelve months.

How has AKTX stock performed over the past year?

Including dividends, AKTX returned -70.0% over the past year, against +12.0% for the S&P 500.

Who are Akari Therapeutics's competitors?

Companies most similar to Akari Therapeutics by business, industry and size include RADX, PPCB, SNY, HSTC, CKDXF.

See a number that looks wrong?